Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? - PubMed (original) (raw)
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Samy Suissa. Diabetes Care. 2018 Jan.
Abstract
Two recent observational studies reported a remarkably lower rate of all-cause death associated with sodium-glucose cotransporter 2 inhibitor (-SGLT2i) use in all patients with type 2 diabetes and not only those at increased cardiovascular risk. The >50% lower mortality rates reported in these studies are much greater than those found in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and CANagliflozin cardioVascular Assessment Study (CANVAS) randomized trials. We show that these observational studies are affected by time-related biases, including immortal time bias and time-lag bias, which tend to exaggerate the benefits observed with a drug. The Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study, based on 166,033 users of SGLT2i and 1,226,221 users of other glucose-lowering drugs (oGLD) identified from health care databases of six countries, was affected by immortal time bias. Indeed, the immortal time between the first oGLD prescription and the first SGLT2i prescription was omitted from the analysis, which resulted in increasing the rate of death in the oGLD group and thus producing the appearance of a lower risk of death with SGLT2i use. The Swedish study compared 10,879 SGLT2i/dipeptidyl peptidase 4 inhibitor (DPP-4i) users with 10,879 matched insulin users. Such comparisons involving second-line therapies with a third-line therapy can introduce time-lag bias, as the patients may not be at the same stage of diabetes. This bias is compounded by the fact that the users of insulin had already started their insulin before cohort entry, unlike the new users of SGLT2i. Finally, the study also introduces immortal time bias with respect to the effects of SGLT2i relative to DPP-4i. In conclusion, the >50% lower rate of death with SGLT2i in type 2 diabetes reported by two recent observational studies is likely exaggerated by immortal time and time-lag biases. It thus remains uncertain whether the benefit seen with empagliflozin in the EMPA-REG OUTCOME trial applies to all SGLT2i and to all patients with type 2 diabetes, not only those at increased cardiovascular risk. While observational studies can provide crucial real-world evidence for the effects of medications, they need to be carefully conducted to avoid such major time-related biases.
© 2017 by the American Diabetes Association.
Comment in
- Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Nyström T, Bodegård J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Nyström T, et al. Diabetes Care. 2018 Jun;41(6):e104-e105. doi: 10.2337/dc18-0339. Diabetes Care. 2018. PMID: 29784707 No abstract available. - Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group. Thuresson M, et al. Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. Diabetes Care. 2018. PMID: 29784708 No abstract available. - Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Suissa S. Suissa S. Diabetes Care. 2018 Jun;41(6):e109-e110. doi: 10.2337/dci18-0015. Diabetes Care. 2018. PMID: 29784709 No abstract available.
Similar articles
- Can we go beyond surrogates?
Drexler A. Drexler A. J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583. J Diabetes. 2017. PMID: 28692750 - Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Shao SC, et al. BMJ Open Diabetes Res Care. 2019 Dec;7(1):e000742. doi: 10.1136/bmjdrc-2019-000742. BMJ Open Diabetes Res Care. 2019. PMID: 32043472 Free PMC article. - Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064 - Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Ghosh RK, et al. Int J Cardiol. 2016 Jun 1;212:29-36. doi: 10.1016/j.ijcard.2016.02.134. Epub 2016 Mar 10. Int J Cardiol. 2016. PMID: 27017118 Review. - Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.
Naing S, Poliyedath A, Khandelwal S, Sigala T. Naing S, et al. Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25. Postgrad Med. 2016. PMID: 27701934 Review.
Cited by
- Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Diabetologia. 2024 Nov;67(11):2585-2597. doi: 10.1007/s00125-024-06251-z. Epub 2024 Aug 23. Diabetologia. 2024. PMID: 39177691 Free PMC article. - Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.
Lv Q, Yang Y, Lv Y, Wu Q, Hou X, Li L, Ye X, Yang C, Wang S. Lv Q, et al. Eur J Med Res. 2024 Jul 31;29(1):399. doi: 10.1186/s40001-024-01954-w. Eur J Med Res. 2024. PMID: 39085898 Free PMC article. - Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
Franchi M, Pellegrini G, Avogaro A, Buzzetti G, Candido R, Cavaliere A, Consoli A, Marzona I, Mennini FS, Palcic S, Corrao G. Franchi M, et al. BMJ Open Diabetes Res Care. 2024 May 27;12(3):e003991. doi: 10.1136/bmjdrc-2023-003991. BMJ Open Diabetes Res Care. 2024. PMID: 38802266 Free PMC article. - Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study.
Park S, Jeong HE, Oh IS, Hong S, Yu SH, Lee CB, Shin JY. Park S, et al. BMJ Open. 2024 Apr 15;14(4):e077084. doi: 10.1136/bmjopen-2023-077084. BMJ Open. 2024. PMID: 38626972 Free PMC article. - Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical